ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05059444 |
Recruitment Status :
Recruiting
First Posted : September 28, 2021
Last Update Posted : September 9, 2022
|
Sponsor:
Guardant Health, Inc.
Information provided by (Responsible Party):
Guardant Health, Inc.
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | September 16, 2021 | ||||
First Posted Date | September 28, 2021 | ||||
Last Update Posted Date | September 9, 2022 | ||||
Actual Study Start Date | September 7, 2021 | ||||
Estimated Primary Completion Date | February 2028 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
Distant Recurrence Free Interval (D-RFi) [ Time Frame: 6 years ] The primary endpoint, distant recurrence-free interval (D-RFi), will be evaluated for each of the primary study cohorts. D-RFi is defined as the time from the end of primary treatment until the time of diagnosis of a distant recurrence of the Index Cancer. Subjects without a distant recurrence will be censored at the time of last follow-up of their Index Cancer.
|
||||
Original Primary Outcome Measures | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures |
|
||||
Original Secondary Outcome Measures | Same as current | ||||
Current Other Pre-specified Outcome Measures |
|
||||
Original Other Pre-specified Outcome Measures | Same as current | ||||
Descriptive Information | |||||
Brief Title | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | ||||
Official Title | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | ||||
Brief Summary | The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment. | ||||
Detailed Description | Not Provided | ||||
Study Type | Observational | ||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Probability Sample | ||||
Study Population | The primary study population will include participants with invasive bladder, ureteral, or renal pelvis carcinoma, NSCLC, or breast cancer with residual invasive disease following neoadjuvant chemotherapy as per inclusion/exclusion criteria defined. Exploratory cohorts include participants with cutaneous melanoma, esophageal carcinoma, gastroesophageal junction carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, epithelial ovarian/Fallopian tube carcinoma, endometrial cancer, and renal cell carcinoma (RCC), as per inclusion/exclusion criteria. Approximately 1,000 total patients will be enrolled into the study. | ||||
Condition |
|
||||
Intervention | Diagnostic Test: Guardant Reveal
Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
|
||||
Study Groups/Cohorts |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Recruiting | ||||
Estimated Enrollment |
1000 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | February 2028 | ||||
Estimated Primary Completion Date | February 2028 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria | Inclusion Criteria:
Primary Study Cohorts
Clinical stage T1-4/N0-3/M0 at presentation AND Completed preoperative systemic chemotherapy-containing regimen AND Underwent definitive surgical resection of the primary tumor AND Has pathological evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes AND Hormone receptor and HER2 status are known Exploratory Cohorts
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | No | ||||
Contacts |
|
||||
Listed Location Countries | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT05059444 | ||||
Other Study ID Numbers | 02-MX-003 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement | Not Provided | ||||
Current Responsible Party | Guardant Health, Inc. | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor | Guardant Health, Inc. | ||||
Original Study Sponsor | Same as current | ||||
Collaborators | Not Provided | ||||
Investigators |
|
||||
PRS Account | Guardant Health, Inc. | ||||
Verification Date | September 2022 |